Billing under medical benefits is a multi-part process requiring considerable expertise to ensure patients receive optimal reimbursement and access to...
If you, or a loved one, has been struggling with a rare or serious health condition, the medicines your doctor suggests you take are likely found only...
Thanks to years of research, advocacy efforts, and awareness campaigns, the spotlight shines more brightly than ever before on rare diseases. More than...
From missed doses to missed refills to misunderstood instructions, the reasons for patient non-adherence to therapies are lengthy and varied. For...
Thanks to a fortunate confluence of focused advocacy, advances in research, and breakthroughs in gene therapy, a much more hopeful era of treatment for...
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease and the most common type of idiopathic interstitial lung disease. IPF...
We’re proud to introduce a few members of Orsini’s team of specialty pharmacists, the engine that drives our patient-centric organization. As we shared...
At a specialty pharmacy, all roads lead to the pharmacist. Pivotal to ensuring effective management of drugs for complex conditions, specialty...
Rare diseases impact individuals and families worldwide. We are honored to participate in Rare Disease Day to help raise awareness for patients living...
Hereditary ATTR amyloidosis (hATTR) is a rare, debilitating genetic condition affecting approximately 50,000 people worldwide. hATTR is characterized...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)